January 14, 2009- FOR IMMEDIATE RELEASE Phoenix, AZ – January 14, 2009 – Mission3, Inc., a leading provider of program delivery for the Life Sciences industry, announced today that Trius Therapeutics selected Mission3 OnDemand as their platform to manage data from discovery of novel drugs to combat Gram-negative biodefense bacterial pathogens in collaboration and support from the National Institute of Allergy and Infectious Diseases (NIAID).
Mission3 OnDemand is a Program Delivery suite that enables Life Science companies to manage their critical information and resources from discovery through regulatory submission. Provided in a tightly integrated, on-demand environment, Mission3 OnDemand includes robust document, project and regulatory submission management along with authoring, collaboration, and publishing (electronic and paper) tools.
“We are pleased to have selected Mission3 as our data delivery partner. The collaboration tools in Mission3 OnDemand are very compelling and will provide high value to Trius as we work with our collaborators to develop drugs directed against biodefense pathogens under the NIAID contract”, said Dr. Ken Bartizal, Chief Development Officer, Trius Therapeutics. “Given its versatility and user-friendly platform, as well as competitive licensing model, Mission3 OnDemand is the most appropriate and versatile system for us to employ in the development of new biodefense prophylaxic and therapeutic drugs with Tetrezolid and other drug discovery initiatives for commercial and biodefense purposes”, said Dr. John Finn, Chief Scientific Officer.
“We are very happy to be working with Trius. Their needs clearly match to the functionality that we deliver to Life Science companies through Mission3 OnDemand. Given the different entities involved in the NIAID contract, Mission3 OnDemand removes silos of information, ensures the project is on track and that everyone has the access to critical documents for communication and submission of data to government agencies that require this information”, said Dirk Karsten Beth, President and Founder of Mission3. “With Mission3’s unique licensing model and comprehensive Program Delivery functionality, Trius can continue to grow and collaborate with new products and partners, as well as utilizing additional functionally, such as, authoring templates and global regulatory submissions as their portfolio expands.”
About Mission3, Inc.
Mission3 is a leading provider of on-demand program delivery software that merges cutting edge technology with affordability, exclusively for the unique needs of the Life Sciences industry. Mission3 OnDemand is a fully integrated, 21 CFR Part 11 compliant, Document, Project, and Regulatory Submission Management suite that is truly web-based and offered in an collaborative, on-demand (SaaS) environment. Designed for rapid deployment and ease of use, Mission3 OnDemand 3.0 manages all documents within business areas governed by world wide regulatory bodies and corresponding submissions. www.mission3.com
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, TR-701, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox®. Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius’ pipeline includes two preclinical programs being developed to treat serious infections including those caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.
